Beyond Air® Announces Participation at Two Upcoming Investor Conferences in March 2023
February 22, 2023 07:00 ET
|
Beyond Air™
GARDEN CITY, N.Y., Feb. 22, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”) a commercial stage medical device and biopharmaceutical company focused on...
Beyond Air® Reports Financial Results for the Third Quarter of Fiscal Year 2023
February 09, 2023 16:05 ET
|
Beyond Air™
U.S. commercial launch continues for LungFit® PH for the treatment of term and near-term neonates with hypoxic respiratory failure Presented positive in vivo combination data with anti-PD1 that...
Beyond Cancer® Appoints Gavin Choy, PharmD as Chief Operating Officer
January 30, 2023 07:00 ET
|
Beyond Air™
GARDEN CITY, N.Y. and HAMILTON, Bermuda, Jan. 30, 2023 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is developing ultra-high concentration nitric...
Beyond Cancer® Announces Sponsored Research Agreement with Stanford and Appointment of Frederick M. Dirbas, MD and Mark D. Pegram, MD to Scientific Advisory Board
January 24, 2023 16:05 ET
|
Beyond Air™
Dr. Dirbas, Associate Professor of Surgery at the Stanford School of Medicine will chair the Scientific Advisory Board (SAB) The new members join Sunil J. Panchal, MD on the Scientific Advisory Board...
Beyond Air® Schedules Third Fiscal Quarter 2023 Financial Results Conference Call and Webcast
January 17, 2023 16:05 ET
|
Beyond Air™
GARDEN CITY, N.Y., Jan. 17, 2023 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a commercial stage medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO)...
Beyond Cancer® Publishes Pre-Clinical Data in Cancer Cell International Demonstrating Its Tumor Ablation Method Utilizing Ultra-High Concentration Nitric Oxide (UNO) Induced a Systemic Response that Prevents Metastases
December 13, 2022 09:25 ET
|
Beyond Air™
GARDEN CITY, N.Y. and HAMILTON, Bermuda, Dec. 13, 2022 (GLOBE NEWSWIRE) -- Beyond Cancer, Ltd., an affiliate of Beyond Air, Inc. (NASDAQ: XAIR) that is focused on developing ultra-high concentration...
Beyond Air® To Participate in Piper’s 34th Annual Healthcare Conference
November 17, 2022 16:05 ET
|
Beyond Air™
GARDEN CITY, N.Y., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR), a medical device and biopharmaceutical company focused on developing inhaled nitric oxide (NO) for the treatment...
Beyond Cancer™ Presents Promising New In Vivo Data Showing Ultra-High Concentration Nitric Oxide Therapy (UNO) in Combination with Anti-PD-1 During the Society for Immunotherapy of Cancer (SITC) 2022 Annual Meeting
November 10, 2022 09:00 ET
|
Beyond Air™
Data showing UNO in combination with anti-PD-1 treatment leads to significantly higher tumor regression rates UNO in combination with anti-PD-1 treatment results in a higher percentage of tumor...
Beyond Air® Reports Financial Results for the Second Quarter of Fiscal Year 2023
November 08, 2022 16:05 ET
|
Beyond Air™
Commercial launch underway for LungFit® PH for the treatment of term and near-term neonates with hypoxic respiratory failure, which received FDA approval on June 28, 2022 Presented favorable safety,...
Beyond Air® Announces Positive Data for Inhaled Nitric Oxide (NO) to Treat COVID-19 with LungFit® PRO in a Poster Presentation at IDWeek 2022
October 24, 2022 07:30 ET
|
Beyond Air™
-- Duration of oxygen support was significantly shorter for subjects treated with inhaled NO LungFit PRO safely delivered 150 ppm NO in the hospital-- GARDEN CITY, N.Y., Oct. 24, 2022 (GLOBE...